Albert N. Marchio II - Dec 28, 2023 Form 4 Insider Report for Fresh Tracks Therapeutics, Inc. (FRTX)

Role
CEO and CFO, Director
Signature
/s/ Griffin D. Foster, Attorney-in-Fact for Albert N. Marchio II (power of attorney previously filed)
Stock symbol
FRTX
Transactions as of
Dec 28, 2023
Transactions value $
-$1,138
Form type
4
Date filed
1/9/2024, 04:10 PM
Previous filing
Jan 26, 2023
Next filing
Apr 10, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FRTX Restricted Stock Units Disposed to Issuer -$1.14K -1.25K -100% $0.91 0 Dec 28, 2023 Common Stock 1.25K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Prior to December 28, 2023, each restricted stock unit ("RSU") represented a contingent right to receive one share of issuer common stock upon settlement. Effective on December 28, 2023, the issuer's board of directors terminated the Fresh Tracks Therapeutics, Inc. (the "Company") 2020 Omnibus Long-Term Incentive Plan (the "Plan") and all unvested RSUs granted under the Plan. The value of the terminated RSUs was replaced with a right to a cash payment valued by multiplying the number of RSUs by the closing price of the Company's common stock on such date (the "Cash Payment").
F2 The Cash Payment will vest in full on the first anniversary of the grant date of the RSUs.